selected publications
- Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. Clinical lymphoma, myeloma & leukemia. 2024 Academic Article GET IT
- Deposition of complement components C5b-9 and MASP2 in tissues is not a feature of GVHD and may assist in discriminating GVHD from thrombotic microangiopathy following allogenic transplantation. Bone marrow transplantation. 2023 Letter GET IT
- Measurable residual disease after CAR T-cell therapy. Seminars in hematology. 2023 Review GET IT
- Screening Chest CT Prior to Allogenic Hematopoietic Stem Cell Transplantation. Transplantation and cellular therapy. 2023 Academic Article GET IT
-
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.
Leukemia & lymphoma.
2020
Academic Article
GET IT
Times cited: 3 -
Getting personal with myelodysplastic syndromes: is now the right time?.
Expert review of hematology.
2019
Review
GET IT
Times cited: 6 -
Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
Expert review of hematology.
2018
Review
GET IT
Times cited: 12